ArticleISRN urology2012
AKT/mTOR as Novel Targets of Polyphenol Piceatannol Possibly Contributing to Inhibition of Proliferation of Cultured Prostate Cancer Cells.
Article in ISRN urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 45 citations in OpenAlex.
- Piceatannol and Pumpkin Seed Oil Synergistically Promote Apoptosis of PC3 Prostate Cancer Cells via Intrinsic Mitochondrial Pathway.ACS omega · 2025Article
- Cancer Prevention and Therapy With Nutritional Science: Addressing the Gap in Medical Education and Practice.MedComm · 2025Review
- The Interplay Between Autophagy and Apoptosis in the Mechanisms of Action of Stilbenes in Cancer Cells.Antioxidants (Basel, Switzerland) · 2025Review
- Anticancer Drug Discovery from Natural Compounds Targeting PI3K/AKT/mTOR Signaling Pathway.Current medicinal chemistry · 2025Review
- Characteristic metabolite profile of 10 colorectal cancer-related bacteria.Frontiers in oncology · 2025Article
- Phytochemicals in Cancer Treatment and Cancer Prevention-Review on Epidemiological Data and Clinical Trials.Nutrients · 2023Review
- Autophagy activation by dietary piceatannol enhances the efficacy of immunogenic chemotherapy.Frontiers in immunology · 2022Article
- Piceatannol, a Structural Analog of Resveratrol, Is an Apoptosis Inducer and a Multidrug Resistance Modulator in HL-60 Human Acute Myeloid Leukemia Cells.International journal of molecular sciences · 2021Article
- Toxicological Evaluation of Piceatannol, Pterostilbene, and ε-Viniferin for Their Potential Use in the Food Industry: A Review.Foods (Basel, Switzerland) · 2021Review
- Prevention of Prostate Cancer in Transgenic Adenocarcinoma of the Mouse Prostate Mice by Yellow Passion Fruit Extract and Antiproliferative Effects of Its Bioactive Compound Piceatannol.Journal of cancer prevention · 2020Article
- Piceatannol Inhibits P. acnes-Induced Keratinocyte Proliferation and Migration by Downregulating Oxidative Stress and the Inflammatory Response.Inflammation · 2020Article
- Piceatannol Suppresses the Proliferation and Induced Apoptosis of Osteosarcoma Cells Through PI3K/AKT/mTOR Pathway.Cancer management and research · 2020Article
- Combinatorial Epigenetics Impact of Polyphenols and Phytochemicals in Cancer Prevention and Therapy.International journal of molecular sciences · 2019Review
- Progress to Improve Oral Bioavailability and Beneficial Effects of Resveratrol.International journal of molecular sciences · 2019Review
- Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate.Oncotarget · 2019Article
- Epigenetic modifications by polyphenolic compounds alter gene expression in the hippocampus.Biology open · 2018Article
- Dietary polyphenols promote resilience against sleep deprivation-induced cognitive impairment by activating protein translation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018Article
- Natural Polyphenols for Prevention and Treatment of Cancer.Nutrients · 2016Review
- Novel application of brain-targeting polyphenol compounds in sleep deprivation-induced cognitive dysfunction.Neurochemistry international · 2015Article
- Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review.Prostate cancer and prostatic diseases · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The polyphenol piceatannol has shown inhibition against tyrosine and serine/threonine kinases. Whether piceatannol also exerts activity on the mammalian target of rapamycin (mTOR), a kinase involved in growth control of eukaryotic cells, is not known. In this study, we tested the effects of piceatannol on proliferation of androgen-dependent (AD) LNCaP and androgen-independent (AI) DU145 and PC-3 prostate cancer (CaP) cells. Suppression of AD and AI CaP cell growth by piceatannol was accompanied by cell cycle blockade in G(1)/S and S phases for LNCaP and PC-3 and induction of apoptosis in DU145 cells. Induction of apoptosis by piceatannol in DU145 cells was evident by reduced expression of poly(ADP-ribose) polymerase (PARP), cleavage of caspase 3 and apoptosis inducing factor AIF, and an increase in cytochrome c. The apoptotic changes occurred in concordance with DNA damage, supported by increased phosphorylated histone H2AX. Immunoblot analyses showed that exposure of different-stage CaP cells to piceatannol also resulted in cell-type-specific downregulation of mTOR and its upstream and downstream effector proteins, AKT and eIF-4E-BP1. We propose that the observed AKT and mTOR changes are new targets of piceatannol possibly contributing to its inhibitory activities on proliferation of CaP cells.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.